Royce & Associates LP lifted its holdings in Enovis Co. (NYSE:ENOV – Get Rating) by 58.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 989,227 shares of the company's stock after purchasing an additional 363,928 shares during the period. Royce & Associates LP owned 1.83% of Enovis worth $45,574,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of the business. Price T Rowe Associates Inc. MD acquired a new stake in shares of Enovis in the 2nd quarter valued at $333,199,000. Cooke & Bieler LP acquired a new position in Enovis during the 2nd quarter worth $86,274,000. State Street Corp acquired a new position in Enovis during the 2nd quarter worth $72,935,000. Eminence Capital LP acquired a new position in Enovis during the 2nd quarter worth $66,263,000. Finally, Millennium Management LLC acquired a new position in Enovis during the 2nd quarter worth $52,132,000. Institutional investors and hedge funds own 96.73% of the company's stock.
Get Enovis alerts:Insider Buying and Selling at Enovis
In other Enovis news, CFO Christopher M. Hix sold 1,367 shares of the business's stock in a transaction dated Wednesday, December 14th. The shares were sold at an average price of $55.28, for a total value of $75,567.76. Following the transaction, the chief financial officer now directly owns 44,605 shares in the company, valued at $2,465,764.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, EVP Daniel A. Pryor sold 67,421 shares of the company's stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $54.58, for a total transaction of $3,679,838.18. Following the transaction, the executive vice president now directly owns 75,731 shares in the company, valued at $4,133,397.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Christopher M. Hix sold 1,367 shares of the company's stock in a transaction that occurred on Wednesday, December 14th. The stock was sold at an average price of $55.28, for a total transaction of $75,567.76. Following the transaction, the chief financial officer now owns 44,605 shares in the company, valued at $2,465,764.40. The disclosure for this sale can be found here. Company insiders own 8.30% of the company's stock.
Wall Street Analysts Forecast Growth
ENOV has been the subject of a number of research analyst reports. Wells Fargo & Company cut their target price on shares of Enovis from $60.00 to $53.00 and set an "equal weight" rating for the company in a research report on Wednesday, October 26th. Robert W. Baird dropped their price objective on shares of Enovis from $73.00 to $68.00 and set an "outperform" rating on the stock in a report on Thursday, November 3rd. Evercore ISI boosted their price objective on shares of Enovis to $68.00 in a report on Tuesday, January 3rd. TheStreet downgraded shares of Enovis from a "c" rating to a "d" rating in a report on Wednesday, November 2nd. Finally, Jefferies Financial Group initiated coverage on shares of Enovis in a report on Wednesday, October 12th. They set a "buy" rating and a $60.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, Enovis has an average rating of "Moderate Buy" and an average price target of $63.50.Enovis Stock Up 0.8 %
NYSE ENOV opened at $58.37 on Thursday. The stock has a market cap of $3.16 billion, a P/E ratio of 121.61 and a beta of 1.99. The company's 50-day simple moving average is $55.14 and its 200 day simple moving average is $53.34. Enovis Co. has a twelve month low of $43.88 and a twelve month high of $134.43.
Enovis (NYSE:ENOV – Get Rating) last released its quarterly earnings results on Wednesday, November 2nd. The company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.47 by $0.12. The firm had revenue of $383.81 million for the quarter, compared to analyst estimates of $379.75 million. Enovis had a net margin of 0.94% and a return on equity of 4.46%. Research analysts anticipate that Enovis Co. will post 2.24 earnings per share for the current year.
About Enovis
(Get Rating)
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.
Read More
- Get a free copy of the StockNews.com research report on Enovis (ENOV)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.